Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1

Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1

Our previous studies have shown that chlorogenic acid (CGA) could significantly improve acute and chronic liver injury through antioxidant and anti-inflammatory activities. However, its effect on non-alcoholic fatty liver disease (NAFLD) are not entirely clear. This study aims to explore the effect...

Full description

Bibliographic Details
Main Authors:	Ameng Shi, Ting Li, Ying Zheng, Yahua Song, Haitao Wang, Na Wang, Lei Dong, Haitao Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Pharmacology
Subjects:	chlorogenic acid non-alcoholic fatty liver disease gut microbiota glucagon-like peptide-1 anti-inflammatory
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.693048/full

Similar Items

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
by: Nyan Abdalqadir, et al.
Published: (2022-10-01)

Grafting chlorogenic acid enhanced the antioxidant activity of curdlan oligosaccharides and modulated gut microbiota
by: Huan Li, et al.
Published: (2024-03-01)

Chlorogenic Acid-Induced Gut Microbiota Improves Metabolic Endotoxemia
by: Xiaolin Ye, et al.
Published: (2021-12-01)

GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
by: Alessandro Mantovani, et al.
Published: (2020-06-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
by: Jinmi Lee, et al.
Published: (2012-08-01)

Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Ebrahim Abbasi Oshaghi
Published: (2017-12-01)

Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson’s disease by regulating gut microbiota
by: Yi Zhang, et al.
Published: (2023-01-01)

Gut microbiota is an endocrine organ
by: Tatiana Y. Demidova, et al.
Published: (2020-12-01)

Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
by: Yuan Zeng, et al.
Published: (2024-01-01)

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet
by: Li Zhao, et al.
Published: (2022-12-01)

Effects of dietary chlorogenic acid on cecal microbiota and metabolites in broilers during lipopolysaccharide-induced immune stress
by: Xiaodi Hu, et al.
Published: (2024-03-01)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
by: L. Kořínková, et al.
Published: (2020-11-01)

GLP-1a: Going beyond Traditional Use
by: Lucas Fornari Laurindo, et al.
Published: (2022-01-01)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
by: Everton CAZZO, et al.
Published: (2016-12-01)

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
by: Takashi Kobayashi, et al.
Published: (2022-10-01)

Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota
by: Ji Yeon Chung, et al.
Published: (2020-11-01)

Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
by: Jing-hua Peng, et al.
Published: (2018-12-01)

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
by: Richard A. Manfready, et al.
Published: (2021-07-01)

GLP-1 receptor agonist as a modulator of innate immunity
by: Jun Chen, et al.
Published: (2022-12-01)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01)

Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications
by: Hirofumi Okubo, et al.
Published: (2018-10-01)

Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children
by: Jiayou Luo, et al.
Published: (2024-04-01)

Chlorogenic Acid Inhibits Ceramide Accumulation to Restrain Hepatic Glucagon Response
by: Na Xiao, et al.
Published: (2023-07-01)

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity
by: Mahafarin Maralani, et al.
Published: (2023-07-01)

The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia
by: Laura Williams, et al.
Published: (2020-07-01)

Maternal Betaine Supplementation Mitigates Maternal High Fat Diet-Induced NAFLD in Offspring Mice through Gut Microbiota
by: Liuqiao Sun, et al.
Published: (2023-01-01)

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
by: Edward S. Bliss, et al.
Published: (2018-07-01)

Association between gut microbiota and NAFLD/NASH: a bidirectional two-sample Mendelian randomization study
by: Qilong Zhai, et al.
Published: (2023-12-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study
by: Ruifang Li, et al.
Published: (2021-01-01)

The benefits of GLP1 receptors in cardiovascular diseases
by: Lamija Ferhatbegović, et al.
Published: (2023-12-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022-12-01)

Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity
by: Xiao-Yu Zhang, et al.
Published: (2020-11-01)

Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
by: T. Y. Demidova, et al.
Published: (2022-03-01)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
by: Ali Asmar, et al.
Published: (2020-08-01)

Editorial: Gut microbiota and gastrointestinal disorders
by: Abbas Yadegar, et al.
Published: (2022-11-01)

Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
by: Yuki Fujiwara, et al.
Published: (2019-07-01)

Acute activation of GLP-1-expressing neurons promotes glucose homeostasis and insulin sensitivity
by: Xuemei Shi, et al.
Published: (2017-11-01)